LONDON--(BUSINESS WIRE)--Technavio has announced its pipeline analysis report on the Hurler syndrome market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat Hurler syndrome.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Hurler syndrome: Market overview
Hurler syndrome is an autosomal recessive disorder, which is caused by the mutation in the iduronidase (IDUA) gene. The two common types of mutation observed in the IDUA gene are W402X and Q70X that consist of mutant alleles. Hurler syndrome is also called as mucopolysaccharidosis type I (MPSI), which happens when the body lacks the alpha-L-iduronidase enzyme, which is needed to break down long chains of sugar molecules.
According to a senior analyst at Technavio for research on infectious and rare diseases, “The body of people suffering from Hurler syndrome fails to produce an enzyme called lysosomal alpha-L-iduronidase. In the absence of this enzyme, GAGs get accumulated significantly, which will damage the organs, including the heart. Many companies are concentrating on developing molecules for the treatment of neurological complications such as Hurler syndromes.”
Hurler syndrome: Segmentation analysis
This market research report segments the Hurler syndrome market based on therapies employed (monotherapy and unknown), RoA (oral, intravenous, intraperitoneal, parenteral, subcutaneous, and unknown), therapeutic modality (gene therapy, small molecule, RNA, stem cell, cell therapy, enzyme, monoclonal antibody, and peptide), targets (hepatic cells, iduronidase gene and sirtuins, insulin receptor, and unknown), MoA (iduronidase replacement, enzyme replacement, cell replacement, and iduronidase gene modulator and sirtuins activator), and recruitment status (recruiting, active not recruiting, completed, and NA).
Monotherapy includes the use of a single drug to treat a disorder or a disease. In the current pipeline, around 63% of the molecules that are being investigated for the treatment of Hurler syndrome are monotherapy.
In case of intravenous RoA, the drug substance is delivered directly into the vein. About 44% of the total molecules that are in the current pipeline are expected to be administered intravenously.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Regulatory Framework
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- RoA
- Therapeutic modality
- Geographical coverage
Recruitment Strategies
- Recruitment status
- Gender
- Age
- Recruitment volume
Key Companies
- Type of players
- Company Overview
Discontinued or Dormant Molecules
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
